ALK and neuroblastoma: In line with a recent report of the therapeutic stratification potential of neuroblastoma patients based on ALK genomic status14, samples with mutations of the second group (including R1275), which are predicted to perturb a phosphosite-mediated dimerization interface in addition to the ATP binding pocket, are characterized by a different distribution of survival times in autonomic ganglia neuroblastoma (ranksum, p = 3.4e−2; Table S3a) and a significantly increased risk across cancers (Cox, p = 2.8e−3; Table S5b).